Biopsy of breast cancer metastases: patient characteristics and survival
Public DepositedAdd to collection
You do not have access to any existing collections. You may create a new collection.
Downloadable Content
Download PDFCitation
MLA
Shachar, Shlomit S, et al. Biopsy of Breast Cancer Metastases: Patient Characteristics and Survival. BioMed Central, 2017. https://doi.org/10.17615/vcyb-ht15APA
Shachar, S., Mashiach, T., Fried, G., Drumea, K., Shafran, N., Muss, H., & Bar Sela, G. (2017). Biopsy of breast cancer metastases: patient characteristics and survival. BioMed Central. https://doi.org/10.17615/vcyb-ht15Chicago
Shachar, Shlomit S, Tanya Mashiach, Georgeta Fried, Karen Drumea, Noa Shafran, Hyman B Muss, and Gil Bar Sela. 2017. Biopsy of Breast Cancer Metastases: Patient Characteristics and Survival. BioMed Central. https://doi.org/10.17615/vcyb-ht15- Creator
-
Shachar, Shlomit S
- Other Affiliation: Division of Oncology, Rambam Health Care Campus, Haifa, Israel
-
Mashiach, Tanya
- Other Affiliation: Statistical Department, Rambam Health Care Campus, Haifa, Israel
-
Fried, Georgeta
- Other Affiliation: Division of Oncology, Rambam Health Care Campus, Haifa, Israel
-
Drumea, Karen
- Other Affiliation: Division of Oncology, Rambam Health Care Campus, Haifa, Israel
-
Shafran, Noa
- Other Affiliation: Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel
- Muss, Hyman B
-
Bar-Sela, Gil
- Other Affiliation: Division of Oncology, Rambam Health Care Campus, Haifa, Israel; Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel; Integrated Oncology and Palliative Care Unit, Rambam Health Care Campus, POB 9602, Haifa 31096, Israel
- Abstract
- Abstract Background Discordance in hormone receptors (HR) and human epidermal growth factor receptor 2 (HER2) status between primary tumors and metastatic sites for breast cancer is well established. However, it is uncertain which patient-related factors lead to biopsy when metastases are suspected and whether having a biopsy impacts survival. Methods The medical charts of metastatic breast cancer (MBC) patients diagnosed January 2000-August 2014 were retrospectively reviewed. A biopsy was defined as a procedure where tissue was obtained and assessed for both HR and HER2. Both bivariate and multivariate analyses were performed to assess patient characteristics related to biopsy and whether having a biopsy was associated with improved survival. Results Of 409 patients suspected of having MBC, 165 (40%) had a biopsy, and 34% of these had discordant HR or HER2 status when compared to the initial diagnosis. In multivariate analysis, having a biopsy was associated with: recurrence in years 2010–2014, disease-free interval of > =3 years, stage 0-IIA at presentation, suspected locoregional recurrence, being HR+/HER2-, or missing HR/HER2 at diagnosis. A similar multivariate analysis revealed that having a biopsy was associated with improved survival (HR = 0.67, p = 0.002). The association of biopsy and improved survival was noted in specific subgroups: patients with missing HR and HER2 data at initial diagnosis (p = 0.001), those without metastases in liver, lung or brain (p = 0.001), and being younger than 70 years old at recurrence (p < 0.001). Conclusions Specific clinical factors were associated with biopsy at the time of suspected recurrence. Having a biopsy was associated with reduced mortality.
- Date of publication
- January 4, 2017
- DOI
- Identifier
- Resource type
- Article
- Rights statement
- In Copyright
- Rights holder
- The Author(s).
- Language
- English
- Bibliographic citation
- BMC Cancer. 2017 Jan 04;17(1):7
- Publisher
- BioMed Central
Relations
- Parents:
This work has no parents.
Items
Thumbnail | Title | Date Uploaded | Visibility | Actions |
---|---|---|---|---|
12885_2016_article_3014.pdf | 2019-05-06 | Public | Download |